[中国单倍型相合造血干细胞移植的现状与未来]
[The present and future of haploidentical hematopoietic stem cell transplantation in China].
作者信息
Mo X D, Huang X J
机构信息
Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):625-628. doi: 10.3760/cma.j.cn121090-20240215-00061.
Abstract
The lack of donors is the biggest obstacle to the widespread use of hematopoietic stem cell transplantation. The establishment and improvement of new transplantation schemes have made haploid hematopoietic stem cell transplantation a clinical routine, benefiting a large number of patients with hematological diseases. Haploid donors have become the most important source of donors for allogeneic hematopoietic stem cell transplantation in China. This article focuses on the current situation and future development trends of haploid hematopoietic stem cell transplantation in China, in order to increase the understanding of clinical doctors on haploid hematopoietic stem cell transplantation.
摘要
供体短缺是造血干细胞移植广泛应用的最大障碍。新移植方案的建立和完善使单倍体造血干细胞移植成为临床常规操作，造福了大量血液病患者。单倍体供体已成为我国异基因造血干细胞移植最重要的供体来源。本文重点介绍我国单倍体造血干细胞移植的现状及未来发展趋势，以提高临床医生对单倍体造血干细胞移植的认识。
相似文献
1
[The present and future of haploidentical hematopoietic stem cell transplantation in China].[中国单倍型相合造血干细胞移植的现状与未来]
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):625-628. doi: 10.3760/cma.j.cn121090-20240215-00061.
2
Editorial: The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation.社论：HLA单倍型相合造血细胞移植的免疫生物学
Front Immunol. 2020 May 20;11:1031. doi: 10.3389/fimmu.2020.01031. eCollection 2020.
3
Editorial: Recent Developments in Haploidentical Hematopoietic Cell Transplantation: Therapy and Complications.社论：单倍型相合造血细胞移植的最新进展：治疗与并发症
Front Immunol. 2021 Aug 17;12:746221. doi: 10.3389/fimmu.2021.746221. eCollection 2021.
4
Advances in haploidentical stem cell transplantation for hematologic malignancies.单倍体相合造血干细胞移植治疗血液系统恶性肿瘤的进展
Leuk Lymphoma. 2016 Aug;57(8):1766-75. doi: 10.3109/10428194.2016.1167204. Epub 2016 Apr 13.
5
Comparable Outcome with a Faster Engraftment of Optimized Haploidentical Hematopoietic Stem Cell Transplantation Compared with Transplantations from Other Donor Types in Pediatric Acquired Aplastic Anemia.在儿童获得性再生障碍性贫血中，与其他供者类型的移植相比，优化的单倍体造血干细胞移植具有更快的植入效果和可比的结果。
Biol Blood Marrow Transplant. 2019 May;25(5):965-974. doi: 10.1016/j.bbmt.2019.01.010. Epub 2019 Jan 11.
6
Who is the best donor for haploidentical stem cell transplantation?谁是单倍体造血干细胞移植的最佳供者？
Semin Hematol. 2019 Jul;56(3):194-200. doi: 10.1053/j.seminhematol.2018.08.003. Epub 2018 Aug 24.
7
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.单倍体与同胞相合供者在成人急性淋巴细胞白血病造血干细胞移植中的结局：欧洲血液和骨髓移植学会急性白血病工作组的一项研究。
J Hematol Oncol. 2021 Apr 1;14(1):53. doi: 10.1186/s13045-021-01065-7.
8
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.单倍体相合自然杀伤细胞在异基因干细胞移植前输注用于髓系恶性肿瘤：一项I期试验
Biol Blood Marrow Transplant. 2016 Jul;22(7):1290-1298. doi: 10.1016/j.bbmt.2016.04.009. Epub 2016 Apr 16.
9
T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia.采用移植后环磷酰胺的T细胞充足的外周血单倍体相合造血细胞移植，在活动性疾病急性髓系白血病中产生的结果与来自传统匹配供体的移植相似。
Biol Blood Marrow Transplant. 2017 Apr;23(4):648-653. doi: 10.1016/j.bbmt.2017.01.068. Epub 2017 Jan 10.
10
Evolution of the role of haploidentical stem cell transplantation: past, present, and future.单倍体相合干细胞移植作用的演变：过去、现在与未来
Expert Rev Hematol. 2020 Aug;13(8):835-850. doi: 10.1080/17474086.2020.1796621. Epub 2020 Aug 4.
本文引用的文献
1
Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial.异体造血干细胞移植后预防慢性移植物抗宿主病的间充质干细胞：一项开放标签随机临床试验。
JAMA Oncol. 2024 Feb 1;10(2):220-226. doi: 10.1001/jamaoncol.2023.5757.
2
Mini-dose methotrexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: A phase 2 trial.小剂量甲氨蝶呤联合甲泼尼龙作为急性移植物抗宿主病的一线治疗：一项2期试验。
J Transl Int Med. 2023 Sep 2;11(3):255-264. doi: 10.2478/jtim-2023-0111. eCollection 2023 Sep.
3
Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis.抢先使用干扰素-α治疗可预防异基因造血干细胞移植后急性髓系白血病复发：真实世界分析。
Front Immunol. 2023 Feb 2;14:1091014. doi: 10.3389/fimmu.2023.1091014. eCollection 2023.
4
Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating "Groot" to heal the world.2022年异基因造血干细胞移植的发展：重塑“格鲁特”治愈世界。
Innovation (Camb). 2023 Jan 2;4(1):100373. doi: 10.1016/j.xinn.2023.100373. eCollection 2023 Jan 30.
5
Hematopoietic Stem Cell Transplantation Activity in China 2020-2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry Group.中国 2020-2021 年 SARS-CoV-2 大流行期间的造血干细胞移植活动：来自中国血液和骨髓移植登记组的报告。
Transplant Cell Ther. 2023 Feb;29(2):136.e1-136.e7. doi: 10.1016/j.jtct.2022.11.011. Epub 2022 Nov 17.
6
Haploidentical transplant for paediatric patients with severe thalassaemia using post-transplant cyclophosphamide and methotrexate: A prospectively registered multicentre trial from the Bone Marrow Failure Working Group of Hunan Province, China.使用移植后环磷酰胺和甲氨蝶呤对重度地中海贫血患儿进行单倍型相合移植：中国湖南省骨髓衰竭工作组的一项前瞻性注册多中心试验。
Br J Haematol. 2023 Feb;200(3):329-337. doi: 10.1111/bjh.18520. Epub 2022 Oct 18.
7
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation.预测单倍型相合造血干细胞移植后急性白血病患者严重急性移植物抗宿主病的综合模型。
Exp Hematol Oncol. 2022 May 3;11(1):25. doi: 10.1186/s40164-022-00278-x.
8
Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial.预防用 NAC 通过改善单倍体 HSCT 后内皮细胞促进造血重建：一项 3 期、开放标签、随机试验。
BMC Med. 2022 Apr 27;20(1):140. doi: 10.1186/s12916-022-02338-9.
9
Adoptive therapy with cytomegalovirus-specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy.同种异体造血干细胞移植后巨细胞病毒感染的细胞因子特异性 T 细胞过继免疫治疗及疗效影响因素
Am J Hematol. 2022 Jun 1;97(6):762-769. doi: 10.1002/ajh.26535. Epub 2022 Mar 25.
10
Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis.巴利昔单抗用于激素难治性急性移植物抗宿主病：一项真实世界分析。
Am J Hematol. 2022 Apr;97(4):458-469. doi: 10.1002/ajh.26475. Epub 2022 Feb 4.
Zotero 插件